AI assistant
Sending…
PULSE BIOSCIENCES, INC. — Director's Dealing 2021
Mar 24, 2021
32093_dirs_2021-03-24_510b58d1-71df-4e2a-b3ac-868f807aef07.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2021-02-23
Reporting Person: UECKER DARRIN (Director, CEO and President)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-23 | Stock Option (right to buy) | $10.66 | A | 37500 | Acquired | 2030-05-18 | Common Stock (37500) | Direct |
| 2021-03-22 | Stock Option (right to buy) | $24.03 | A | 54750 | Acquired | 2031-03-22 | Common Stock (54750) | Direct |
Footnotes
F1: Represents the acquisition of vested options upon the determination of the Compensation Committee of the Board of Directors of the Issuer that certain performance conditions were met in 2020 with respect to performance-based stock options granted to the Reporting Person on May 18, 2020.
F2: The shares subject to the option will vest in equal annual installments over the following four years on the anniversary of March 1, 2021, subject to the Reporting Person's continued service through each vesting date.
More from PULSE BIOSCIENCES, INC.
Regulatory Filings
2026
Jun 10
Interim / Quarterly Report
2026
May 14
Proxy Solicitation & Information Statement
2026
May 11
Capital/Financing Update
2026
May 6
Earnings Release
2026
May 4
Investor Presentation
2026
Apr 27
Investor Presentation
2026
Apr 16
Board/Management Information
2026
Apr 9
Regulatory Filings
2026
Apr 7
Board/Management Information
2026
Mar 27